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Modulations of the potentially toxic transition metals iron (Fe) and copper (Cu) are impli-
cated in the neurodegenerative process in a variety of human disease states including
amyotrophic lateral sclerosis (ALS). However, the precise role played by these metals is
still very much unclear, despite considerable clinical and experimental data suggestive of
a role for these elements in the neurodegenerative process.The discovery of mutations in
the antioxidant enzyme Cu/Zn superoxide dismutase 1 (SOD-1) in ALS patients established
the first known cause of ALS. Recent data suggest that various mutations in SOD-1 affect
metal-binding of Cu and Zn, in turn promoting toxic protein aggregation. Copper home-
ostasis is also disturbed in ALS, and may be relevant to ALS pathogenesis. Another set
of interesting observations in ALS patients involves the key nutrient Fe. In ALS patients,
Fe loading can be inferred by studies showing increased expression of serum ferritin, an
Fe-storage protein, with high serum ferritin levels correlating to poor prognosis. Magnetic
resonance imaging of ALS patients shows a characteristic T2 shortening that is attributed
to the presence of Fe in the motor cortex. In mutant SOD-1 mouse models, increased
Fe is also detected in the spinal cord and treatment with Fe-chelating drugs lowers spinal
cord Fe, preserves motor neurons, and extends lifespan. Inflammation may play a key
causative role in Fe accumulation, but this is not yet conclusive. Excess transition met-
als may enhance induction of endoplasmic reticulum (ER) stress, a system that is already
under strain in ALS. Taken together, the evidence suggests a role for transition metals in
ALS progression and the potential use of metal-chelating drugs as a component of future
ALS therapy.
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INTRODUCTION
The burden of amyotrophic lateral sclerosis (ALS) is very sig-
nificant with a world-wide disease incidence of 2 in 100,000
(Chio et al., 2013). It is a rapidly debilitating neuromuscular dis-
order characterized by loss of motor neurons from the cerebral
cortex, brainstem, and spinal cord. Progressive muscle weakness,
wasting and paralysis then follow with death typically occurring
3–5 years post-diagnosis. Approximately 95–90% of ALS cases are
sporadic (sALS) while the balance is genetically linked familial dis-
ease (fALS), where mutations in superoxide dismutase 1 (SOD-1)
cause 25% of cases. At least 160 mutations in SOD-1 have been
associated with fALS and sALS (Sreedharan and Brown, 2013).
With the possible exception of mutant SOD-1, which forms
toxic protein aggregates, the etiology of this disease is still unclear.
Other postulated mechanisms of neuronal death in ALS include
glutamate excitotoxicity (Rothstein, 2009), excessive generation of
reactive oxygen and nitrogen species (Barber and Shaw, 2010),
mitochondrial dysfunction (Rothstein, 2009), induction of endo-
plasmic reticulum (ER) stress (Atkin et al., 2008), axonal deterio-
ration, and deposition of toxic ubiquitinated neuronal inclusions,
where transactive response DNA binding protein 43 kDa (TDP-
43) and fused in sarcoma (FUS) are major protein components
(Arai et al., 2006; Rothstein, 2009). Many of these mechanisms are
inter-connected and “snowballing” effects can be envisaged where
events trigger, and/or exacerbate, others.
A common thread that links a variety of neurodegenerative
conditions is the build-up of the transition metals iron (Fe) and
copper (Cu) in the CNS (for review see Hadzhieva et al., 2013a;
Jellinger, 2013). Ordinarily, these metals are incorporated into a
wide range of vital enzymes, as their redox capability enables an
efficient biochemical “switch” function, but this means that their
homeostasis must be tightly regulated in order to prevent exces-
sive production of reactive oxygen species that can damage cellular
components. Alzheimer’s diseases (AD) and Parkinson’s diseases
(PD), in particular, show marked brain and/or CNS increases in
these metals and much attention has focused on the role of these
metals in these conditions.
In AD, Fe and Cu are thought to play roles in the formation
of amyloid-β plaques and tau neurofibrillary tangles (Hane et al.,
2013; Savelieff et al., 2013) and recent magnetic resonance image
(MRI) studies showed elevated Fe in the hippocampus in AD
patients correlating to decreased structural integrity of the hip-
pocampus, possibly caused by a process of demyelination (Raven
et al., 2013). An interesting speculation by these authors was that
demyelination could generate a vicious cycle of further Fe depo-
sition as myelin contains significant Fe. However, there is still
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controversy surrounding the role of Fe in AD, as others have failed
to find elevated Fe in AD brain, leading to the suggestion that
a citation bias exists in the literature favoring studies reporting
increased brain Fe in AD (Schrag et al., 2011).
Accumulation of α-synuclein in Lewy bodies in the substan-
tia nigra is the primary pathological hallmark of PD and results
in the death of dopaminergic neurons. A variety of experimental
evidences suggest that Fe and Cu not only facilitate aggregation
of α-synuclein, but also potentiate the toxicity of these deposits
(Santner and Uversky, 2010; Rose et al., 2011).
Despite controversy, chelation therapy targeting Fe and/or Cu
has been advocated for AD and PD with encouraging results in
some AD clinical trials with the chelators desferrioxamine (Crap-
per McLachlan et al., 1991) and clioquinol (Ritchie et al., 2003).
However, the clinical value of lowering metals in these conditions
still requires further validation.
A variety of other neurodegenerative disorders also show dis-
turbances in Fe and/or Cu metabolism, leading to excess (or
reduced) loading of these metals. These include the other α-
synucleinopathies, a variety of disorders grouped together as“neu-
rodegeneration with brain iron accumulation” (NBIA), multiple
sclerosis, Huntington’s disease, Wilson’s disease, Menkes disease,
Friedreich’s ataxia, and the prion diseases (for reviews see Spillan-
tini and Goedert, 2000; Hagemeier et al., 2012; Rouault, 2013).
That Fe, Cu, and zinc (Zn) may have a role in the patho-
physiology of human ALS is highlighted by a diverse range of
recent studies (2011–2013) showing that (a) higher concentra-
tions of serum ferritin (an Fe-storage protein reflecting high body
Fe levels) correlate to poor prognosis in ALS patients (Ikeda et al.,
2012; Nadjar et al., 2012); (b) Fe accumulation in the motor cor-
tex is responsible for frequently observed MRI abnormalities in
ALS patients (Langkammer et al., 2010; Kwan et al., 2012; Ignja-
tovic et al., 2013); (c) inappropriately chelated Fe (i.e., capable of
promoting free-radical generation) was found in the CSF of ALS
patients but not normal controls (Ignjatovic et al., 2012); (d) in a
group of 51 ALS patients, the levels of magnesium (Mg) (p< 0.01),
Fe (p< 0.05), Cu (p< 0.05), and Zn (p< 0.10) in CSF were higher
than those in controls, with some patients showing very high lev-
els of Cu and Zn before showing critical clinical deterioration
(Hozumi et al., 2011). These studies build on a multitude of others
that have shown a variety of disturbances in Fe/Cu/Zn metabolism
leading to metal deposition or dysfunction of key metalloenzymes
in ALS (Oshiro et al., 2011).
Also of interest is the link between mutations in the hemochro-
matosis gene (HFE; principally the H63D polymorphism) and
sALS; mutations which are thought to induce prolonged ER
stress possibly through an Fe-overloading mechanism (Liu et al.,
2011b). Other observations also support the possibility that excess
redox-active metals may enhance ER stress in ALS by perturbing
redox status, disrupting normal protein folding, and modulating
ER/cytosolic calcium balance.
ALS and other neurodegenerative conditions are also accompa-
nied by chronic neuroinflammation. Evidence shows that inflam-
mation modulates the expression of several key proteins of Fe
homeostasis, and can result in further neuronal Fe accumulation,
but this potentially significant inter-play has yet to be fully
explored in ALS.
Providing a therapeutic proof-of-principle argument in the
role of these metals in ALS are studies in SOD-1 mutant mice
where at least three different Fe (Jeong et al., 2009; Wang et al.,
2011) and five Cu/Zn-chelating agents have shown significant
rescue effects (Hottinger et al., 1997; Nagano et al., 2003; Petri
et al., 2007; Tokuda et al., 2008). Several chelators were also
able to reverse, in part, the dysregulation of Fe or Cu in SOD-
1 models, reducing microglial activation that seems to occasion
neuronal loss and significantly extended lifespan. Overexpression
of the endogenous metal-binding protein, metallothionein (MT)
(Tokuda et al., 2014), or treatment with the Cu-chelate and Cu(II)-
ASTM (Soon et al., 2011) also increased survival of mutant SOD-1
mice, demonstrating a variety of rescue effects.
Taken together, these divergent data suggest that transition met-
als play some role in the neurodegenerative process in ALS. How-
ever, considerable gaps in our knowledge remain and in this review
we seek to provide an overview of the latest research together with
perspectives on future research and clinical implications.
Fe METABOLISM IN THE BRAIN AND CNS: GENERAL
OVERVIEW
Iron homeostasis in the body begins by tight control of Fe release
from enterocytes in the small intestine by the hormone hepcidin
(Hp). Generally acknowledged as the master regulator of Fe home-
ostasis, Hp prevents enterocyte Fe release into the blood by binding
to ferroportin-1 (Fpn). It is produced mainly by hepatocytes but is
also expressed in mouse and human CNS and brain (Zechel et al.,
2006; Wang et al., 2010). The major blood Fe-transport molecule is
transferrin (Tf) and most cell types, including neurons, acquire Fe
by a process where plasma Tf complexes with Tf-receptors (TfR)
on the cell surface with subsequent internalization by endocytosis
(Figure 1). Following Tf–TfR complex internalization to endo-
somes, where lower pH results in the release of Fe3+ from Tf, a
ferric reductase, possibly six-transmembrane epithelial antigen of
the prostate family member 3 (STEAP3), or duodenal cytochrome
B (dcytb) then reduces Fe3+ to Fe2+ facilitating binding to diva-
lent metal transporter 1 (DMT1) and endosomal export to the
cytosol (Figure 1). In terms of the brain, plasma Tf and other
proteins of Fe metabolism do not cross the blood–brain barrier
(BBB). Hence, an additional CNS Fe-acquisition step is required,
essentially an iteration of the above process, where plasma Tf
binds to TfR present on the luminal membrane of cerebrovas-
cular endothelial cells. Following cytosolic release, Fe is exported
across the endothelial membrane into interstitial space where it can
be acquired by neurons (by the same TfR-mediated mechanism)
or bound to low-molecular weight ligands (citrate and lactoferrin,
among others) for non-transferrin-bound-iron (NTBI) cell uptake
(Figure 1). Interestingly, microglia principally take up NTBI facil-
itated by DMT1 and lactoferrin (Benarroch, 2009; Snyder and
Connor, 2009). Typically high in ferritin, microglia are thought
to play a role in the maintenance of Fe homeostasis in neurons
and when activated, have been shown to release Fe from ferritin
mediated by superoxide (Yoshida et al., 1995). To date, the only
molecule known to efflux Fe from neurons is Fpn whose inter-
nalization in neuronal cells is regulated by Hp and ceruloplasmin
(Cp) (Benarroch, 2009; Song et al., 2010; Zheng and Monnot,
2012). Iron in neuronal cells is mostly bound to ferritin or stored
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FIGURE 1 | Key features of Fe and Cu uptake and release by the
neuron. Iron (Fe) is either acquired by non-transferrin bound Fe (NTBI)
from low-molecular weight complexes with citrate or ascorbate or by
endocytosis of the transferrin (Tf)-transferrin receptor complex (TfR). Once
endocytosed, a decrease in pH and the action of a ferrioxidase enables
Fe2+ release to the labile Fe pool (LIP) by divalent metal transporter 1
(DMT1) where it may be stored in the Fe-storage protein ferritin, or
directed to organelles such as lysosomes. Copper (Cu) uptake occurs at
neuron surface by copper transporter-1 (CTR1). Following endocytosis,
Cu2+ ions are incorporated into Cu-metallothionein (Cu-MT), cytochrome c,
or superoxide dismutase 1 (SOD-1). Ferroportin (Fpn), the only known Fe
exporter from neurons, relies on the Cu-containing metalloenzymes
hephaestin (Hep) or ceruloplasmin (Cp) for activity. Hepcidin (Hp) activity
can internalize Fpn.
in the lysosome. Ferritin is the major Fe-storage protein and is
an endogenous iron chelator (Cozzi et al., 2010). An important
ferritin sub-type is mitochondrial ferritin (mitFtn), which reg-
ulates mitochondrial Fe level and Fe-related oxidization (Arosio
et al., 2009). Lysosomes are also important Fe pools, acquiring
Fe by turnover of Fe-containing proteins such as cytochrome c
(Johansson et al., 2010). Due to their acidic nature, lysosomes
contain Fe in the more redox-promoting Fe2+ state (Terman
and Kurz, 2013). Controlling intracellular Fe levels are the iron
regulatory protein (IRP)/iron responsive element (IRE) and the
hypoxia-inducible factor (HIF)/HIF-responsive elements (HREs)
(for review see Wang and Pantopoulos, 2011). Significantly, HREs
are present within the TfR1 and DMT1 genes, and HIF regulates
Fpn activity by inhibition of Hp (Wang and Pantopoulos, 2011).
Recently, Hp was found to cause Fe overload in a rat model of cere-
bral ischemia (Ding et al., 2011), reflecting Hp’s well-characterized
ability to bind to Fpn, inducing its cellular internalization, thereby
reducing Fe export (Nemeth et al., 2004).
COPPER AND IRON: PEAS IN A POD
Like Fe, Cu is a highly useful redox-active metal incorporated
into many Cu-containing enzymes such as cytochrome c oxidase,
SOD-1, monoamine oxidase, and dopamine β-monooxygenase,
which play important biological roles (Zheng and Monnot, 2012).
Cu is absorbed from the small intestine and delivered to the liver
and kidneys where it is predominately (65–90%) bound to Cp
(Sharp, 2004). Cellular Cu transport and homeostasis involve the
membrane Cu transporters copper transporter-1 (CTR1), DMT1,
and Cu exporter ATPases (ATP7A and ATP7B). Delivering Cu to
specific intracellular targets are the Cu chaperone proteins antiox-
idant protein-1 (ATOX1), cytochrome oxidase enzyme complex
(COX17), and Cu chaperone for SOD (CCS) (Harris, 2001).
Playing a key role in Fe metabolism are the Cu-containing fer-
rioxidases Cp and hephaestin (Hep). Cp catalyzes the conversion
of ferrous iron (Fe2+) to ferric (Fe3+), which is then transferred to
Tf (Sharp, 2004) with Cp, and/or the multi-Cu-centered protein
Hep, playing an essential role in the efflux of Fe via Fpn from ente-
rocytes (Sharp, 2004). Significantly, Fpn is highly expressed in the
epithelial cells of the choroid plexus and plays a key role in Fe efflux
from the CNS (Figure 1). Accordingly, a decrease in Hep activity is
suggested to “contribute to iron accumulation in the brain during
copper deficiency” (Skjorringe et al., 2012). Additionally, Cu defi-
ciency is known to lower GPI-anchored Cp in mouse/rat spleen
and liver – and it is speculated that Cu deficiency may lower GPI-
anchored Cp in astrocytes (Mostad and Prohaska, 2011). As noted
above, Fe efflux from neurons is mediated chiefly by Fpn whose
internalization is regulated by Hp (Nemeth et al., 2004; Song et al.,
2010). Conversely, components of the Fe-transport pathway are
also Cu responsive. For instance, the Fe transporter DMT1 is also
a physiologically relevant Cu transporter (Sharp, 2004). Hence,
both Fe and Cu homeostasis can be considered interdependent,
with one affecting the other (Figure 1).
ALTERED Fe METABOLISM IN MUTANT SOD-1 CELL AND
MOUSE MODELS
A variety of perturbations in Fe metabolism at the mRNA and
protein level have been reported in both SOD-1(G37R) and SOD-
1(G93A) mutant ALS mice. In late-stage disease (12 months)
SOD-1(G37R) mice, a caudal-to-rostral pattern of mRNA expres-
sion of a number of proteins involved in Fe uptake and export
was seen. Specifically, the mRNA levels of DMT1, TfR1, Fpn, and
Cp were highest rostrally (i.e., in the cervical region) compared
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to the caudal (lumbar) region (Jeong et al., 2009). Western blot-
ting also showed the same expression pattern of these proteins.
As DMT1 was expressed at twofold greater levels than either
Fpn or Cp, this suggested a potential for greater Fe influx,
compared to Fe efflux. Increased caudal-to-rostral spinal cord
expression of the Fe-storage protein ferritin was also noted
in 12-month-old SOD-1(G93A) mice. Interestingly, the mRNA
expression of these proteins in younger pre-symptomatic mice
(4-month-old) showed a reverse pattern of DMT1, Fpn, and Cp
mRNA expression, i.e., higher lumber but lower cervical expres-
sion (Figure 2A), suggesting that Fe accumulation begins before
significant neurodegeneration is evident.
These observations correlate to the pattern of Fe deposition and
neuronal loss in the spinal cords of these mice, placing Fe “at the
FIGURE 2 | (A)The caudal-to-rostral (tail-to-head) pattern of mRNA
expression of iron metabolism proteins in young and old SOD-1(G37R) mice
provides circumstantial evidence that Fe is involved in the
neurodegenerative process. Advanced neurodegeneration and Fe loading is
evident in the lumbar region 12-month-old mice, where 8 months earlier,
the expression pattern of proteins of Fe metabolism favored net Fe
accumulation. (B)Treatment of SOD-1(G37R) mice with the Fe chelator SIH
extends lifespan in SOD-1(G37R) mice. SOD-1(G37R) mice were given SIH
either once or twice a week (n=12) from 8 months of age, a Kaplan–Meier
graph shows the percentage of animals surviving with age. (C,D) Vehicle
control treated 50 week-old SOD-1(G37R) mice showed loss of neurons
whereas SIH treatment results in neuronal preservation (arrows) as
indicated by cresyl violet-stained lumbar spinal cord tissue sections. Scale
bar, 50µM. [(B–D) reproduced with permission and minor modification
from Jeong et al., 2009].
scene of the crime,” i.e., at 12 months these mice show advanced
neurodegeneration in the lumbar region (where 8 months earlier,
Fe began accumulating) but less in the cervical and thoracic spinal
cord (where the pattern of dysregulation now favors net Fe accu-
mulation). However, other explanations of neuronal Fe loading
are also possible. An in vivo model of disrupted axonal trans-
port was also shown to lead to Fe loading in large ventral horn
motor neurons (Jeong et al., 2009) and an increase in inflamma-
tory mediators can also result in Fe accumulation (see below).
While there is no direct evidence that excess Fe is responsible for
neuronal loss, the injurious consequences of excess intracellular
Fe are well known. That an Fe chelator was able to limit neuronal
loss in this model (see below) also implies that Fe has at least some
role in the neurodegenerative mechanism/s. Similar changes in
the mRNA expression of these Fe metabolism proteins were also
found in SOD-1(G93A) mice, but no Fe loading was detected by
Perl’s staining (Jeong et al., 2009).
Considering that disturbances in mitochondrial function are
also believed to play a significant role in ALS, it is interesting to
note that immunofluorescence staining showed a marked increase
in mitochondrial ferritin protein (mitFtn) in the ventral horn
motor neurons and astrocytes in 12-month-old SOD-1(G37R)
mice but not wild-type mice of the same age mice (Jeong et al.,
2009). Overexpression of mitFtn has been shown to trap Fe in
the mitochondria, hence Jeong et al. inferred increased mitochon-
drial Fe and speculated that an increased mitochondrial Fe load
in neurons and glia could cause neurodegeneration as occurs in
Friedreich’s ataxia (Jeong et al., 2009).
Wang et al. (2011) also examined Fe metabolism in the SOD-
1(G93A) ALS model and the ability of Fe chelators to medi-
ate rescue effects (discussed below). Besides finding a 148 and
180% increase in spinal cord Fe in SOD-1 G93A mice (90- and
120-day-old, respectively) compared to age-matched WT mice,
these authors also showed induction of TfR1 protein expres-
sion. Considering that a major Fe-acquisition pathway in neurons
involves intracellular delivery of Fe via the TfR, upregulation
of this protein may, in part, explain the increased Fe loading.
Additionally, this result also confirms a general dysregulation
of Fe homeostasis, as ordinarily, TfR expression decreases in
response to increased intracellular Fe (Richardson and Ponka,
1997).
Fe homeostasis in SOD-1(G93A) ALS was further studied using
transgenic neuroblastoma SH-SY-5Y cells stably transfected with
WT SOD-1 or the G93A mutated human SOD-1 gene (Hadzhieva
et al., 2013b). In agreement with studies in SOD-1(G37A) mice,
increased mRNA levels of TfR1, ferritin, and DMT1 were found.
Additionally, effects on Fe homeostasis within the mitochondrion,
a key site for the generation of Fe–sulfur cluster precursor proteins
leading to heme biosynthesis, were examined. A 2–3.7 fold increase
in mitFtn1&2, iron–sulfur cluster scaffold protein (IScU), and
frataxin (Fxn) mRNA was found to also correlate to increased pro-
tein expression with the exception of Fxn. Mutant SOD-1(G93A)
cells were also significantly Fe loaded compared to WT cells (1.6
fold when normalized to cell number), but interestingly, iso-
lated mitochondria were not Fe-loaded. Further experiments then
sought to dissect the mechanism of TfR upregulation. As noted
above, Fe deprivation induces classical TfR upregulation via IRE
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sensing in IRP1 however, Fe supplementation failed to decrease
TfR expression, indicating a key dysregulation in Fe homeosta-
sis whereby TfR expression is induced in SOD-1(G93A) mutant
cells by IRE/IRP1 independent mechanism/s. ROS is an alternative
inducer of TfR expression and has been shown to result in liver Fe
loading in alcoholic liver disease (Kohgo et al., 2008). Experiments
utilizing H2O2 and retinoic acid to induce ROS in SOD-1(G93A)
mutant cells showed increases in TfR, Ftn, mitFtn1&2, and DMT1
mRNA compared to WT cells, the authors suggesting that ROS-
induced upregulation of the Fe importing system may “create a
vicious cycle generating strong oxidative stress” (Hadzhieva et al.,
2013b).
RESCUE EFFECTS BY Fe CHELATORS IN SOD-1 MOUSE
MODELS OF ALS
Treatment of SOD-1(G37R) ALS mice with the lipophilic Fe chela-
tor SIH increased mean lifespan by 5 weeks (Figure 2B). Histolog-
ical staining showed that there were more surviving motor neurons
in SIH-treated SOD-1(G37R) ALS mice compared with vehicle-
treated SOD-1(G37R) mice of the same age (Jeong et al., 2009;
Figures 2C,D). In untreated 12-month-old SOD-1(G37R) mice,
significant accumulation of Fe was evident in motor neurons of
lumbar ventral horn which also appeared atrophied. Glial cells also
showed Fe loading. SIH treatment reduced fivefold to sixfold the
number of Fe-containing cells detected by Perl’s staining of spinal
cord sections, reversed the significant weight loss observed in
untreated SOD-1(G37R) mice and improved locomotor function
(Jeong et al., 2009).
More recently, Wang et al. (2011) showed that the brain-
permeable Fe chelators VK-28 and M30 significantly delayed ALS
onset, extended lifespan and reduced spinal cord motor neu-
ron loss in the SOD-1(G93A) transgenic mouse model of ALS.
Both Fe chelators significantly attenuated the elevated Fe level
and TfR expression, decreased oxygen free radicals and sup-
pressed microglial and astrocytic activation in the spinal cords
of SOD-1(G93A) mice (Wang et al., 2011).
Another mechanistic effect of M30 and structurally related
chelators is induction of hypoxia-inducible factor-1α (HIF-
1α), possibly through enhanced phosphorylation of the p42/44
mitogen-activated protein kinase (MAPK)/ER kinase (MEK) and
protein kinase C (PKC) signaling pathways (Avramovich-Tirosh
et al., 2010). As a transcriptional activator, HIF-1α is known to
regulate a range of neuroprotective signaling pathways and treat-
ment with M30 was shown to increase the gene expression of
erythropoietin (EPO), vascular endothelial growth factor (VEGF),
enolase 1 and inducible nitric oxide synthase (iNOS) in NSC-34
cells (Kupershmidt et al., 2009), and rat primary embryonic corti-
cal neurons (Avramovich-Tirosh et al., 2010). In vivo mice studies
with M30 showed upregulation of HIF-1α protein in brain (cor-
tex, hippocampus, and striatum) and spinal cord when given over
30 days. Enhanced HIF-1α levels coincided with increased gene
expression of EPO, VEGF, iNOS, glucose transporter 1 (GLUT-1),
and heme oxygenase-1 (HO-1) in one or more brain regions but
only VEGF showed upregulation in the spinal cord. Additionally,
M30 in vivo also increased mRNA expression of brain-derived
neurotrophic factor (BDNF) and glial cell-derived neurotrophic
factor (GDNF) as well as the antioxidant enzymes catalase, SOD-1,
and glutathione peroxidase (GPx) in spinal cord and some brain
regions (Kupershmidt et al., 2011).
The induction of VEGF by M30 is particularly interesting in
light of the many studies demonstrating a neuroprotective role of
VEGF in ALS (for review see Llado et al., 2013). Indeed, genetic
studies link polymorphisms in the VEGF gene to the development
of sALS (Lambrechts et al., 2003; Lysogorskaia et al., 2012) and
VEGF therapy has been shown to prevent motor neuron degener-
ation and increase survival in mutant SOD-1 mice (Storkebaum
et al., 2005; Wang et al., 2007). On the basis of these and other
observations, VEGF is a suggested therapeutic intervention for
ALS. Besides M30, other Fe chelators including desferrioxamine
(DFO; the standard clinically used Fe chelator for Fe overload)
have also been shown to induce VEGF expression in non-ALS
models (Beerepoot et al., 1996).
ALTERED Fe DISTRIBUTION AND METABOLISM IN ALS
PATIENTS
In ALS patients, there are several indications of dysregulated iron
metabolism. Increased serum ferritin levels and lower Tf (but
increased Tf saturation) were recently reported by Nadjar et al.
(2012) in a cohort of 694 ALS patients and 297 healthy controls.
High serum ferritin was correlated to reduced survival time in
ALS patients by 300 days compared to ALS patients with low level
serum ferritin. Although serum Fe levels were not significantly
different between ALS patients and controls, increased Tf satu-
ration could suggest Fe loading. Previously, Ikeda et al. (2012),
assessing a range of serum biomarkers in 92 Japanese ALS patients
and 92 age-matched healthy controls, also found that increased
serum ferritin correlated with clinical deterioration. Increased fer-
ritin was also reported (Goodall et al., 2008; Qureshi et al., 2008)
together with lower serum Tf (Mitchell et al., 2010) in ALS patients.
The latter study found that, as biomarkers, higher serum ferritin
and lower Tf discriminated between ALS patients and controls
with 82% accuracy. These authors also quantified light-chain fer-
ritin (L-ferritin) suggesting that increased L-ferritin might reflect
activation, and potentially Fe turnover, in macrophages or brain
microglia. Goodall et al. also assessed the levels of C-reactive
protein, reporting that high serum ferritin was independent of
expression of this inflammation marker.
High Fe in ALS patients has also been detected by MRI scan-
ning techniques that attribute characteristic T2 hypointensities
in images of the motor cortex to Fe deposition. Most recently,
assessment of 19 ALS cases and 19 healthy controls attributed 3T
and 7T FLAIR hypointensities in the hand-knob region of the
motor cortex to high Fe which correlated to higher upper motor
neuron impairment scores (Kwan et al., 2012; Figures 3A,B). Sub-
sequent postmortem investigations in an ALS patient confirmed
that 7T MRI hypointensity changes in the middle and deep layers
of the motor cortex correlated to the same regions as a positive
Perls’ DAB Fe stain (Figure 3C). Interestingly, higher magnifica-
tion images seemed to suggest that positive Perl’s DAB staining
was present in cells resembling microglia, but was not evident in
spinal motor neurons (Kwan et al., 2012; Figure 3D). Immunos-
taining experiments indicating that excess Fe was stored in ferritin
in microglia, as co-localization was shown for ferritin and the
microglial marker CD6. It was also noted that luxol fast blue stain
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FIGURE 3 | Iron (Fe) accumulation in the motor cortex of an ALS patient.
The 7T magnetic resonance imaging (MRI) scans reveal Fe accumulation in
the motor cortex hand-knob region in a 51-year-old ALS patient (A) (arrows),
compared to a healthy control. (B) Postmortem Fe accumulation in the middle
and deeper layers of cortical gray matter and at the gray–white junction by
Pearl’s staining (arrowheads indicate the pial surface while arrows indicate the
gray–white junction). (C) At higher magnification, Pearl’s staining detects Fe in
cells with irregular processes suggestive of microglia in the ALS motor cortex.
(D) Scale bars: C, 1 mm; D, 10µM. Reproduced with permission and minor
modification from Kwan et al. (2012).
showed myelin pallor in the subcortical white matter of the pre-
central, compared to the postcentra, gyrus (Kwan et al., 2012),
which is potentially interesting in light of the recent suggestion by
Bartzokis et al. that demyelination may contribute to excess Fe in
AD (Raven et al., 2013). Other studies have also attributed changes
in T2 MRI images to Fe build-up in ALS patients (Oba et al., 1993;
Langkammer et al., 2010; Ignjatovic et al., 2013).
Increases in bulk Fe levels had previously been detected in ALS
patient ventral horn (Kurlander and Patten, 1979), although not
in other studies. Another indication of disturbed Fe distribution
may be the presence of higher levels of reactive low-molecular
weight Fe species in the CNS. Electron paramagnetic resonance
(EPR) spectrometry studies showed that ALS patients had higher
levels of inappropriately liganded Fe in the CNS (i.e., bidentate or
tridentate ligands that leave spare Fe coordination site/s thereby
increasing Fe solubility, in-turn promoting Fe redox cycling and
•OH production; Ignjatovic et al., 2012).
IRON AND NEUROINFLAMMATION
Microglial activation and astrogliosis are primary hallmarks of the
neuroinflammatory environment and widely present in a variety
of human neurodegenerative conditions, including ALS (McGeer
et al., 1993). They are also a noted feature in mutant SOD-1 mice
models of ALS (Jeong et al., 2009; Wang et al., 2011).
Microglia and astrocytes have been shown to play a role in scav-
enging (and storing) excess Fe, thereby protecting neurons from
consequences of Fe loading (Pelizzoni et al., 2013). However, it
has been recognized that inflammation modifies the expression
of the key Fe-regulating hormone Hp (Nicolas et al., 2002; Ganz,
2003), in turn, down-regulating the Fe export molecule Fpn, and
leading to Fe accumulation (Nemeth et al., 2004). This is an ele-
ment of the classical host Fe-withdrawal defense against infection
and inflammation. While there is no direct evidence of a sim-
ilar process occurring in ALS, interesting clues are provided by
studies in dopaminergic neurons. In a study of lipopolysaccha-
ride (LPS)-induced PD in the rat, activated microglia increased
expression of the pro-inflammatory cytokines IL-1 and IL-6 and
Fe loading was evident in the substantia nigra. Reduced expres-
sion of Fpn was also found. In further experiments, SH-SY5Y
dopaminergic neurons incubated with media enriched in pro-
inflammatory cytokines showed decreased Fpn expression and the
appearance of Fe deposits (Zhang et al., 2014). Increased levels of
iron regulatory protein 1 (IRP1), transferrin receptor 1 (TfR1),
and Hp had previously been observed in IL-1β or tumor necro-
sis factor alpha (TNF-α) treated ventral mesencephalic neurons
(Wang et al., 2013). Additional experiments showed LPS-induced
activated microglia led to enhanced IL-1β and TNF-α release upon
Fe loading.
Matrix metalloproteinases (MMPs) are also known mediators
of neuroinflammation. Increased Fe loading of LPS-stimulated
rat microglial (HAPI) cells was shown to enhance secretion of
MMP-9 and MMP-1. Increased cellular Fe levels also impaired
zymosan phagocytic activity in activated microglia (Mairuae et al.,
2011). Others have hypothesized that in addition to activated
microglia, Fe maybe deposited in the CNS by infiltrating circula-
tory monocytes. Once transformed into phagocytic macrophages,
and subsequently dying back post-consumption of compromised
neurons, these cells may re-release Fe into the labile Fe pool (LIP),
enhancing the potential of oxidative stress damage to adjacent cells
(including neurons; Andersen et al., 2013).
Collectively, these results are suggestive of the possibil-
ity of a vicious cycle whereby Fe loading of microglia and
astrocytes increases mediators of neuroinflammation, but in-
turn, microglial/astroglial Fe loading results from inflammation-
mediated suppression of Fpn by Hp. As yet, there is no direct
evidence of these processes occurring in ALS, but processes similar
to these may provide a potential explanation for the characteris-
tic T2 hypointensities in MRI images of the motor cortex due to
Fe deposition and increased serum ferritin in ALS patients. These
observations also underscore the general anti-inflammatory prop-
erty of Fe and Cu chelators in murine SOD-1 ALS models, as
evidenced by reduced microglial activation (Jeong et al., 2009;
Kupershmidt et al., 2011).
COPPER IN ALS
Most interest in Cu in ALS centers on mutations in SOD-1 and
over 160 mutations have been associated with ALS (Sreedha-
ran and Brown, 2013). Formation of toxic SOD-1 aggregates is
strongly implicated (Chattopadhyay and Valentine, 2009; Sreed-
haran and Brown, 2013) and multiple data describe defective
Cu (and Zn) binding by various SOD-1 mutants (Carri et al.,
1994; Eum and Kang, 1999; Hayward et al., 2002). Early studies
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showed that the Cu chelators diethyldithiocarbamate and peni-
cillamine could reverse mutant SOD reactivity (Wiedau-Pazos
et al., 1996). Undermetallation of SOD-1 seems to be a signifi-
cant factor in SOD-1 aggregation in vivo (Hayward et al., 2002;
Lelie et al., 2011). Studies in SOD-1 mutant mice showed that
SOD-1 fractions isolated from spinal cords mutant SOD-1 mice
that were insoluble (i.e., aggregated) were Cu and Zn depleted,
whereas soluble SOD-1 fractions were highly metalated (Lelie et al.,
2011). A re-distribution of Cu from gray to white matters corre-
lated to areas of high SOD-1 and increased Zn was also found
in the white matter in mutant SOD-1 mice (Lelie et al., 2011).
In a study of mutant H43R SOD-1, a rapidly progressing form
of fALS, metal-replete (halo) H43R SOD-1 exhibited a stable β-
barrel structure, but apo-H43R SOD-1 was unstable and readily
misfolded (Fujimaki et al., 2013). Spectroscopic studies showed
that Cu2+ binding differed between the halo- and apo-forms, the
authors suggesting that bound Cu2+ in the apo-H43R form was
pro-oxidant. While SOD-1 metalation status appears important
in promoting aggregation, failure of SOD-1 maturation, due to
disrupted formation of a stabilizing intra-subunit disulfide bond
also, appears to be significant (Seetharaman et al., 2009). Irre-
spective of the precise aggregation mechanism, SOD-1 aggregates
are thought generally to acquire a “toxic gain of function” related
to promotion of oxidative stress. Impairment of axonal transport
(De Vos et al., 2007) and mitochondrial dysfunction (Li et al.,
2010) could also be sequelae. More recently, SOD-1 mutants were
found to interfere with protein transport between the ER–Golgi
apparatus, leading to Golgi fragmentation and induction of ER
stress (Atkin et al., 2013). Others have suggested that palmitoyla-
tion (a reversible post-translational modification that influences
structure, function, and localization) of SOD-1 mutants could
increase their targeting to cellular membranes, potentially increas-
ing their propensity to cause mitochondrial dysfunction or ER
stress (Antinone et al., 2013).
Other Cu-containing enzymes or chaperones showing modu-
lations of expression or activity in ALS patients include Cp and
MT. An early Polish study assessing the levels of Cp in 14 ALS
patients found suppressed levels in eight patients (Domzal and
Radzikowska, 1983) but this was not replicated in other studies
(Boll et al., 2008; Goodall et al., 2008). However, a recent study of
Cp isoforms in ALS showed that patients had higher abundance
of non-sialylated protein forms of Cp, indicating “a Cp functional
impairment” (Conti et al., 2008). Further evidence suggestive of
role for Cp emerged from a proteomic 2D difference-in-gel elec-
trophoresis analysis of CFS in ALS patients (Brettschneider et al.,
2010). Compared to controls, only six proteins were found to
be modulated between these groups, the ceruloplasmin precursor
protein (CpPP) and the Fe delivery protein Tf were two proteins
that were downregulated (Brettschneider et al., 2010).
Studies with the endogenous antioxidant chaperone MT also
provide insight into the important role played by Cu in mutant
SOD-1 ALS. In a cohort of 12 ALS patients, the immunohis-
tochemical expression of the MT-1/2 isoform was significantly
reduced in the spinal cord relative to the control group, although
both MT-1/2 and MT-3 were found in glia (Hozumi et al., 2008).
Expression of MT-3 in astrocytes in the gray matter of the lumbar
spinal cord negatively correlated with ALS duration. Additionally,
patients with MT-3-positive neurons also showed MT-3 positive
glia. Previous studies had shown that SOD-1(G93A) mice with
either MT-1/2 or MT-3 knocked-down had accelerated ALS dis-
ease course (Nagano et al., 2001) and recently SOD-1G93A mice
engineered to also overexpress MT showed significantly enhanced
survival together with reduced motor neuron loss and degen-
eration of ventral root axons and skeletal muscle atrophy. Glial
activation was also reduced. Additionally, SOD-1 aggregates in the
spinal cord glia were reduced in double transgenic mice (Tokuda
et al., 2014).
Aside from its role in SOD-1 and other metalloenzymes or
chaperones, there is some evidence of general Cu accumulation
in human ALS. Most recently, 52 ALS patients showed a signif-
icant (p < 0.05) increase in Cu in CSF (Roos et al., 2013), but
no excess of Cu was found in CSF by others (Boll et al., 2008).
Slightly elevated Cu and Zn were also found in erythrocytes in
SOD-1 fALS patients (Vinceti et al., 2002). In a study of spinal
cord tissue from sALS patients found a significant Cu increase
(Kurlander and Patten, 1979). Accumulations of Cu have also
been noted in the SOD-1(G93A) mouse (Li et al., 2006; Tokuda
et al., 2013), prompting assessment of various Cu chelators in
this model, including d-penicilamine (Hottinger et al., 1997)
and trientine (Nagano et al., 2003). Most recently, the Cu chela-
tor tetrathiomolybdate (TM) was shown to significantly improve
symptoms and survival in SOD-1(G93A) ALS mice (Tokuda et al.,
2008) by removal of Cu from the Cys111 residue in mutant SOD-1
but not from histidyl sites essential for SOD-1 enzymatic activ-
ity, thereby preventing “aberrant copper chemistry.” Subsequently,
an almost threefold accumulation of Cu in spinal cords of SOD-
1(G93A) mice was reversed by TM treatment and modulations
in expression of a variety of Cu-containing proteins in SOD-1
mutants were reported (Tokuda et al., 2013). Specifically, in the
G93A, G127X, G85R, and D90A SOD-1 mutants, western blots
showed significantly increased expression of Steap2, Atox1, CTR1,
and CCS (all except the G127X mutant) and significant decrease
in Atp7a in spinal cord tissue. The functional significance of these
modulations was described as skewing the Cu-transport system
toward Cu accumulation in the spinal cord (Tokuda et al., 2013).
Additional support for a deleterious role of Cu in mutant SOD-
1 ALS was provided by studies with Tg mice engineered to contain
both SOD-1G86R and mottled/brindled (MoBr) mutations (Kiaei
et al., 2004). The latter is a model of Menkes disease, a human
genetic disorder causing copper deficiency. In SOD-1G86R/MoBr
mice spinal cord, Cu was reduced by 60%, and these mice lived
9% longer than mice bearing the SOD-1G86R mutation alone,
supporting a role for Cu in SOD-1-related fALS.
ENDOPLASMIC RETICULUM STRESS: AN
UNDER-RECOGNIZED ROLE FOR IRON?
Triggers of ER stress include Ca2+ storage defects, lipid/glycolipid
imbalances, oxidative stress, and a variety of environmental insults
such as viral infections and drug exposure (Rutkowski and Kauf-
man,2007). In ALS,major ER stress inducers are misfolded SOD-1,
TDP-43, and/or FUS proteins that accumulate in the ER thereby
inducing the unfolded protein response (UPR) (Atkin et al., 2008).
The UPR acts to reduce ER stress by re-establishing normal
protein folding and proceeds by the activation of three distinct ER
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stress transduction pathways following removal of the ER chap-
eron binding immunoglobulin protein (BiP) from the luminal
domains of inositol-requiring enzyme-1 (IRE1), protein kinase R
(PKR)-like endoplasmic reticulum kinase (PERK), and activating
transcription factor 6 (ATF6). However, severe or chronic UPR
triggers apoptosis (Bertolotti et al., 2000; Figure 4).
In human ALS patients, a variety of indicators of ER stress
leading to induction of the UPR have been identified. A group
of 12 sALS patients showed a 26-fold higher positive immunos-
taining for the ER chaperone protein GRP78 (also known as BiP)
compared to controls (Sasaki, 2010) and in the spinal cords of
sALS patients, UPR induction was demonstrated by upregula-
tion of stress sensor kinases (IRE1, ATF6, and PERK), chaperones
protein disulfide isomerase (PDI), ER protein 57 (Erp57), apop-
totic mediators CCAAT/-enhancer-binding protein homologous
protein (CHOP), and caspase 4 (Atkin et al., 2008).
It is well appreciated that Fe overload increases intracellular
ROS (Galaris and Pantopoulos, 2008), a known initiator of ER
stress. More specific observations of the link between Fe and
ER stress include upregulation of the ER chaperons BiP and
calreticulin (CRT) in Fe-loaded astrocytoma (Ye and Connor,
2000); increased BiP expression in the livers of dietary Fe-loaded
mice (Petrak et al., 2007); reduced mRNA and protein expres-
sion of the major blood Fe transporter Tf was found in trans-
fected Hep 3B hepatoma cells overexpressing CHOP (You et al.,
2003; Figure 4). Mutations in the hemochromatosis gene (HFE)
have also been associated with sALS. Both the H63D and C282Y
HFE polymorphisms interfere with the ability of HFE to limit
Fe uptake from Tf, which results in Fe loading (Feder et al.,
1998; Lee et al., 2007). Recently, human neuronal SH-SY5Y cells
with a tetracycline-controlled FLAG-tagged HFE H63D muta-
tion showed upregulation of the UPR markers BiP, PDI, and
IRE1α after tetracycline treatment (Liu et al., 2011b). Induc-
tion of the master Fe-regulating hormone Hp by ER stress has
also been noted (Vecchi et al., 2009) with subsequent down-
stream effects on the expression of the cellular Fe exporter, Fpn,
and ferritin. These studies were the first to demonstrate the
reciprocal relationship between Fe homeostasis and ER stress,
describing Hp induction as a marker of ER stress (Vecchi et al.,
2009).
INTRACELLULAR CALCIUM SIGNALING IS ALSO
RESPONSIVE TO Fe
Calcium (Ca2+) storage defects are thought to be significant in
ALS and another potential consequence of excess Fe in ALS may
be detrimental modulation of Ca2+ signaling. Early observations
showed that the ROS generating Fe2+/H2O2 couple decreased
Ca2+ uptake by skeletal sarcoplasmic reticulum (SR) (Stoyanovsky
et al., 1994; Castilho et al., 1996) by inhibiting the activity of the
Ca2+ pump Ca2+-ATPase (SERCA) (Moreau et al., 1998) which
transfers Ca2+ from cytosol into SR lumen (Figure 4). However,
Fe2+ given alone enhanced Ca2+ uptake into rat heart SR vesicles,
mimicking ruthenium red by direct inhibition of the ryanodine
receptor (RyR), one of the channels by which Ca2+ is released
from the SR (Kim et al., 1995). Interestingly, the ER stress inducer
thapsigargin also inhibits SR Ca2+-ATPase (thereby reducing ER
lumen Ca2+ uptake) and was shown to increase Fe uptake in K562
leukemic cells with depletion of intracellular Ca2+ or chelation of
FIGURE 4 | Impact of excess iron (Fe) on indicators of ER stress and
calcium (Ca2+) signaling. ER stress results in the activation of the IRE1,
PERK, and ATF6 apoptotic pathways. Loss of BiP induces oligomerization
of IRE1 or PERK or activates ATF6 which downstream results in JNK or
CHOP mediated apoptosis. High Fe in cells and animal models has been
shown to induce BiP, CHOP, and calrectulin (CRT) expression. Excess Fe
and resultant redox processes may inhibit function of the SERCA Ca2+
pump, decreasing ER Ca2+ levels, and leading to CHOP induction, on the
other hand, Fe has been shown to inhibit the ryanodine receptor (RyR)
ER Ca2+ exporter. Induction of CRT by Fe could suggest that Fe
participates in causing protein mis-folds or results in perturbed Ca2+
balance in the ER.
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extracellular Ca2+ resulting in inhibition of Fe uptake (Ci et al.,
2003).
Additionally, Fe was shown to be necessary for Ca2+ signal gen-
eration and ERK1/2 stimulation induced by the glutamate agonist
N -methyl-d-aspartate (NMDA), as Fe chelation reduced Ca2+ sig-
nal duration and prevented NMDA-induced ERK1/2 activation
(Munoz et al., 2011). Fe supplementation of primary hippocam-
pal neurons kept in Ca2+-free medium also elicited Ca2+ signals,
suggesting that hippocampal neurons require Fe to generate RyR-
mediated Ca2+ signals after NMDA receptor stimulation (Munoz
et al., 2011). Hp treatment of human osteoblasts was also shown to
increase intracellular Ca2+, an effect potentiated by added Fe (Li
et al., 2012). Pretreatment of osteoblasts with a L-type Ca2+ chan-
nel blocker or a RyR antagonist inhibited Ca2+ release from the SR,
demonstrating that the increase of intracellular Ca2+ induced by
Hp probably reflected Ca2+ release from the ER, triggered by Ca2+
influx (Li et al., 2012). Interestingly, mRNA and protein expression
of the ER chaperone CRT that plays a key role in protein folding
protein in the ER, was shown to increase with Fe concentration
(Liu et al., 2011a), suggesting that CRT induction may be part of
the cellular response to excess Fe, which in turn could affect ER
Ca2+ buffering. Considering that CRT functions as a misfolded
protein chaperone, CRT induction could suggest that excess Fe
may also negatively impact protein folding.
A ROLE FOR METALS IN TOXIC TDP-43 ACCUMULATIONS?
Neuronal cytoplasmic inclusions of TDP-43 are a major compo-
nent of ubiquitinated protein aggregates found in the CNS of spo-
radic MND patients. Indeed, TDP-43 inclusions are a histopatho-
logical feature in the vast majority of MND patients (Da Cruz
and Cleveland, 2011). Current thinking suggests these inclusions
mediate neuronal damage by inducing ER stress or by affecting
RNA processing (Atkin et al., 2008).
Interestingly, several lines of evidence also point to the role
for metals in TDP-43 accumulation and toxicity. In SH-SY5Y
neuronal-like cells expressing endogenous TDP-43, Zn treatment
reduced TDP-43 expression but enhanced the formation of TDP-
43 positive inclusions (Caragounis et al., 2010). However, addi-
tion of Cu or Fe did not induce similar effects, suggesting that
specific Zn-associated processes might modulate TDP-43 accu-
mulation. Additionally, treatment of SOD-1(G93A) mice with
the Cu-containing chelate, Cu-ASTM, prevented the accumu-
lation of abnormally phosphorylated and fragmented TDP-43
in the spinal cord (Soon et al., 2011). The Fe chelator M30
and a structural analog also showed reduced TDP-43 accumu-
lation in the SOD-1(G93A) model (Wang et al., 2011). Another
clue emerged from a phenotypic screen for small molecules that
could reverse TDP-43 toxicity in yeast. One class of “hit” com-
pounds were 8-hydroxyquinolines, biologically active metal chela-
tors structurally related to clioquinol, the authors suggesting that
8-hydroxyquinolines may be able to target TDP-43 accumulation
by altering metal homeostasis (Tardiff et al., 2012). It was also
recently reported that mice bearing the TDP-43(A315T) muta-
tion had increased Cu, Zn, and manganese (Mn) in the spinal
cords not evident in wild-type mice (Dang et al., 2014). Increased
levels of the monocyte chemoattractant protein-1 (MCP-1) in
TDP-43(A315T) mouse spinal cord indicated microglial activation
and inflammation. Protein oxidation was also higher in TDP-
43(A315T) spinal cord and is a hallmark of metal-mediated Fenton
chemistry. How and why TDP-43 inclusions alter the metallic land-
scape of the spinal cord in SOD-1 ALS will be an on-going research
interest.
DISCUSSION
The transition elements Fe and Cu are involved in ALS progres-
sion by potentially multiple mechanisms. A clear role is evident
for Cu and Zn in the key enzyme SOD-1. Mutations affecting
the metal-binding sites may lead to structural instability, possibly
through loss of integrity of a intra-subunit disulfide bond, and
then leading to accumulation and/or to a toxic gain of function.
Other Cu-containing enzymes may also be relevant in ALS pro-
gression. Early data implicated reduced Cp expression, but this was
not reproduced in other studies, but higher levels of non-sialylated
Cp were detected in another study in ALS patients and could indi-
cate a Cp functional impairment. Reduced expression of MT has
also been noted in ALS patients and in SOD-1(G93A) models.
Conversely, MT overexpression or treatment rescues phenotype
in mutant SOD-1 mice. Studies in patients and SOD-1 mice also
show bulk increases in Cu in the spinal cord. That a variety of
Cu chelators also extend lifespan and reverse pathophysiological
effects in SOD-1 mouse models, provide evidence suggestive a role
for Cu in ALS progression.
In sALS patients, high serum ferritin levels have been consis-
tently shown to correlate with ALS progression and characteristic
MRI T2 shortening shows Fe overload in the motor cortex of
ALS patients. To what extent this excess Fe drives the ALS dis-
ease process is unknown (although there are some clues provided
by SOD-1 models) and it is likely that excess Fe loading represents
a process secondary to primary disease mechanism/s.
As a biomarker, increased serum ferritin may infer increased
body iron stores, but not necessarily so, as infection or inflam-
mation can also induce its expression. However, increased Fe and
inflammation are linked and one exacerbates the other creating a
vicious cycle. Indeed, a relatively good case, albeit circumstantial,
can be made that excess Fe in ALS is a consequence of inflam-
matory processes. That Goodall et al. reported increased serum
ferritin in ALS patients in the absence of an increase of the inflam-
matory marker C-reactive protein, does not necessarily rule out a
role for inflammation in serum ferritin induction (and Fe deposi-
tion), as more discrete localized inflammation could have occurred
that did not generate a detectable serum trace. However, increases
in Tf saturation, in addition to high serum ferritin reported by
Nadjar et al., also point to excess Fe. Besides inflammation, another
potential mechanism that could cause Fe loading in ALS could be
reduced Cp expression or activity, as Cp plays a role in mediating
Fe export by Fpn.
The form in which Fe is present also influences its degree of
danger. Low-molecular weight labile Fe is more hazardous than
Fe stored in ferritin. But Fe in ferritin is still bioavailable and can
readily be released by activated microglia in a process mediated by
superoxide. Increased labile Fe, or “inappropriately chelated” Fe,
reported by Ignjatovic et al. in ALS patient CSF also suggests that
excess Fe in ALS is present in a form that can readily contribute to
redox stress.
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As models of fALS, mutant SOD-1 mice reproducibly show
Fe loading in spinal cord, and in SOD-1(G37R) mice, dysregula-
tion of Fe metabolism resulting in neuronal Fe loading precedes
significant neuronal loss, providing at least circumstantial evi-
dence that Fe is involved in the neurodegenerative process. The
ability of a variety of structurally diverse Fe chelators to extend
lifespan, prevent neuronal loss and mediate other rescue effects
provides additional evidence that Fe is probably involved in the
neurodegenerative process in ALS.
Induction of ER stress due to aggregation of protein mis-folds
in ALS is gaining traction as a major mechanism of neuronal loss.
Various studies describe how excess Fe may increase ER stress, as
Fe loading causes increases in the expression of a variety of ER
chaperones. Perturbed intracellular Ca2+ signaling can also be an
expected consequence of Fe loading due to inhibition of ER Ca2+
pumps. Another link to ER stress and transition metals is provided
by recent studies showing enrichment of TDP-43 aggregates with
Cu, Zn, and other metals. In the context of a system already under
stress, it is intriguing to speculate that transition metal loading in
ALS may also be enhancing ER stress. However, no direct evidence
yet exists for this hypothesis.
While the collective evidence is strengthening, the insult that
excess transition metals render in ALS still requires clarification.
However, as a facet of a complex disease, lowering (or modulating)
levels of transition metals, particularly Cu and Fe, in ALS would
seem to be an avenue worth pursuing.
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